source
- Triveni Bio raises $65M ahead of upcoming readouts on eczema drugsTriveni Bio announced a $65 million Series C after its second asset for eczema entered clinical studies last month. The Series C was co-led by Ascenta Capital and Janus Henderson Investors and incl…Endpoints · 1mo ago↗ source
- Migraine biotech Vedana Therapeutics makes its debut with $46M Series AVedana Therapeutics has emerged from stealth with $46 million in Series A proceeds with the goal of developing treatments that could free patients from migraines entirely. Available treatments for…Endpoints · 1mo ago↗ source
- Health groups say HHS is trying to 'rush reinstatement' of ACIPA group of health organizations has accused HHS of trying to use a “self-created crisis” to “rush reinstatement” of the CDC’s frozen vaccine advisory panel. The committee and its recommendations ar…